GenomeWeb's Neil Versel gets an update on LifeOmic & the Indiana Precision Health Initiative

"Startup LifeOmic, which offers gene sequencing and related informatics technologies, is less than a year old, yet it seems poised to go where few health IT companies have gone before: aggregation and analysis of both clinical and omics data to support actual patient care."

See full GenomeWeb story Here (Premium Account Access required).


LifeOmic Leverages Genomenon’s Mastermind Genomic Search Engine for Variant Interpretation

For Immediate Release October 18, 2017

LifeOmic Partners with Genomenon to Streamline Genomic Interpretation of Whole Genomes

ANN ARBOR, Mich – October 18, 2017 – LifeOmic has signed an agreement with Genomenon to use the Mastermind Genomic Search Engine to streamline clinical interpretation of LifeOmic’s genome sequencing data. Through this partnership, LifeOmic will automate prioritization of their genome sequencing data for clinical patients by annotating disease-causing variants with citations from relevant biomedical literature. By providing immediate insight into published scientific literature, Mastermind speeds the variant interpretation process by helping scientists at LifeOmic decide which variants are likely associated with disease and important for clinical care and which are likely benign and can be safely ignored.

Dramatic advances in DNA sequencing technology hold great promise for personalized medicine, but challenges remain. As the cost and time associated with sequencing decrease, the industry is faced with the daunting challenge of how to store and analyze vast amounts of patient data to drive physicians’ decisions on diagnosis and treatment. LifeOmic has built a proprietary analytic platform with advanced informatics to process and analyze a patient’s whole genome to unlock the tremendous value hidden within this data.

Mastermind connects patients’ DNA mutations with citations from the scientific literature to understand the clinical impact of each mutation. Having indexed over 5.5 million scientific articles for every disease, gene and variant, Mastermind comprehensively identifies all clinically relevant and prioritized articles.

LifeOmic and Genomenon are co-presenting “Faster, Comprehensive Variant Curation For Whole Genome Sequencing” on Wednesday October 18th at the American Society of Human Genetics to formally announce their partnership. Tom Barber, CSO at LifeOmic, will present how LifeOmic is using DNA sequencing, big data analytics and Mastermind to advance the development of precision medicine.

About LifeOmic:

LifeOmic is a rapidly growing technology company pioneering the use of DNA sequencing and big data analytics to advance the development of precision medicine. The LifeOmic Precision Medicine PlatformTM is a secure cloud service for the long-term storage, retrieval, analysis and clinical use of genomic and other medical information.  LifeOmic’s founder and CEO Don Brown, MD is one of Indiana’s most successful entrepreneurs. Dr. Brown founded two of the first three software companies in Indiana to be publicly traded on NASDAQ.

For more information, visit www.lifeomic.com.

About Genomenon:

Genomenon has eliminated the manual search process for gene and variant curation with its genomic search engine for use in clinical decision-making. By indexing millions of genomic-related scientific articles, Genomenon has created the only comprehensive genome-specific search engine to enable pathologists and geneticists to quickly and accurately curate disease-causing variants from genome sequence data.

For more information, visit www.genomenon.com or email sales@genomenon.com.

Press Contacts:

Genomenon: Jessica Francis 440.840.4987 or email jessicafrancisPR@gmail.com

LifeOmic: David Fuller 317.258.1031 or email David.Fuller@LifeOmic.com


IU, Regenstrief, LifeOmic Announce Collaboration to Revolutionize Medicine

INDIANAPOLIS – Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.

Under terms of the agreement, LifeOmic receives a blanket license to a broad range of intellectual property owned by IU and Regenstrief as well as access to faculty. In return, IU and Regenstrief receive a minority equity position in LifeOmic. The strategic agreement will greatly facilitate collaboration across the three partners, removing traditional barriers between for-profit and not-for-profit organizations.

“Indiana University’s expertise in precision health research, combined with the Regenstrief Institute’s long history of innovation in medical records data and LifeOmic’s impressive capabilities in genomic data storage and management, make for a powerful partnership that will help our institutions collaborate to improve health in Indiana and beyond,” said IU President Michael A. McRobbie, PhD. “We look forward to seeing the discoveries that will stem from this alliance of academia and industry.”

The mapping of the human genome has made it possible to discover the underlying genetic causes of diseases in individuals and to tailor therapy based on that information. But the field of genomics also poses new challenges, as vast volumes of data must be analyzed, stored and incorporated into physicians’ decisions about diagnoses and treatments.

LifeOmic will work with scientists at IU and Regenstrief to develop a “data commons” to store genetic and other medical data for millions of patients within a single repository. The result will be a platform that can be used by researchers and clinicians around the state to make discoveries and improve the delivery of personalized health care.

The agreement also enables individual investigators at IU and Regenstrief to seamlessly collaborate with LifeOmic on other projects. For example, an IU immunologist might work with LifeOmic to develop a test to help physicians more efficiently and accurately diagnose autoimmune disorders. Such partnerships with industry are common but typically require separate, time-consuming negotiations for each project.

“The problems and challenges we are facing in health care today are too big to be solved by any one institution,” said Anantha Shekhar, MD, PhD, IU associate vice president of research for university clinical affairs and executive associate dean for research affairs at IU School of Medicine. “To make progress, we must collaborate with other universities and with private industry across multiple fields. My vision is to forge more industry partnerships like this with minimal bureaucratic barriers to collaborations, so we can tap into the expertise we need to serve patients in Indiana and elsewhere.”

Regenstrief President and CEO Peter J. Embi, MD, and LifeOmic founder and CEO Don Brown, MD, also praised the potential benefits for patients and the state of Indiana.

“The work we will do through this partnership will leverage all of our strengths and expertise to build systems that will support the future of health care,” Dr. Embi said. “We could not be more excited to work across our organizations to realize this vision and develop innovative systems that improve the health of people everywhere.”

“We’re excited to work with IU and Regenstrief to build a platform that can not only advance the delivery of precision medicine but serve as the basis for an entire ecosystem of health care innovation in Indiana,” Dr. Brown said. “We hope to see dozens of new companies spring up to take advantage of the tremendous opportunities ahead.”

About the collaborators

IU School of Medicine is the largest medical school in the United States and offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities. In June 2016, the school launched the Precision Health Initiative, the first of IU’s Grand Challenge research initiatives, with the goals of leveraging precision medicine to cure at least one cancer and one childhood disease, and to find ways to prevent one chronic illness and one neurodegenerative disease.

The Regenstrief Institute is a pioneer in health informatics, having developed many of the technologies and approaches that are now common across electronic health records and health information exchanges. Innovations developed at Regenstrief have helped make Indiana one of the most health-wired states in the country. Regenstrief Institute’s informatics experts and software engineers are actively working to build the infrastructure that will support incorporating genomic data and standards into electronic health record systems and routine health care.

LifeOmic is a rapidly growing technology company pioneering the use of DNA sequencing and big data analytics to advance the development of precision medicine. The LifeOmic Precision Medicine Platform™ is a secure cloud service for the long-term storage, retrieval, analysis and clinical use of genomic and other medical information. LifeOmic’s founder and CEO Don Brown, MD is one of Indiana’s most successful entrepreneurs. Dr. Brown founded two of the first three software companies ever to go public in Indiana – Software Artistry and Interactive Intelligence. Interactive Intelligence was acquired by Genesys Telecommunications Labs in 2016. At the time of the sale, Dr. Brown donated $30 million to the IU School of Medicine to found a new immunotherapy center to fight cancer and other diseases.

##

Media Contacts:

Andrea Zeek

317-278-2886

anzeek@iu.edu

David Fuller

317-258-1031

david.fuller@lifeomic.com

Lisa Welch

317-274-9234

llwelch@regenstrief.org

 


LifeOmic Announces HIPAA Compliance Statement

LifeOmic Announces HIPAA Compliance!

Feel free to view our HIPAA Executive Statement and Signed Attestation.  Organizations can feel secure working with LifeOmic for a variety of  services -- we ensure HIPAA compliance regarding all data and services offered.

View HIPAA Statement


Brown calls genomics startup ‘riskiest thing I’ve ever done’ - Indiana Business Journal

"Don Brown founded LifeOmic to try to help solve just that problem by enabling doctors like Abonour to practice genomics-based precision medicine. And the 6-month-old firm has already got some wind in its sails.

Precision medicine tailors treatment based on an individual’s unique attributes—coded in DNA. The 23 pairs of chromosomes in each human cell contain about 30,000 protein-making genes that can determine the effectiveness of certain treatments, from blood thinners to cancer-fighting drugs.

LifeOmic has two main offerings: sequencing of a patient’s genome (the full set of DNA information) and data-management software. The latter is a cloud-based service for the storage, retrieval, analysis and clinical use “of genomic and other digital information increasingly central to patient care,” company officials said, and it comes with “decision-support” capabilities."

Read article here.


LifeOmic CEO Don Brown Delivers IUSM 2017 Commencement Address

LifeOmic CEO Don Brown, MD shares his professional journey from being an unconventional medical student at Indiana University School of Medicine to becoming it's largest donor in 2016.  Don's remarks begin at 25:09 and end at 51:33.

Watch video here. 

 


LifeOmic goes live with MasterControl laboratory quality management solution

LifeOmic goes live with MasterControl laboratory quality management solution.

 


LifeOmic Discusses RTP Plans With Triangle Business Journal

Triangle Business Journal reports on LifeOmic's anticipated business plans for the Research Triangle Park area:

With local ties in hand, Brown is now heading a new company called LifeOmic – following the close of Interactive Intelligence’s sale Dec. 1

“We’re looking to disrupt the precision medicine space,” says Jeff Swartz, LifeOmic’s chief operating officer.

LifeOmic – which has $20 million in funding, according to its website – plans to bring in experts from areas such as cloud computing, bioinformatics and genomics to create “a new precision medicine solution that spans multiple data sources” says Swartz.

The company currently employs nine people, and Swartz says he expects that number to be at 30 to 35 people by mid-summer. He says that 10 to 15 of those employees will likely be based in RTP.

 


Inside Indiana Business Television Interview With Don Brown

Inside Indiana Business with Gerry Dick highlights Don Brown’s $30 million gift to establish the Brown Center for Immunotherapy at the University of Indiana School of Medicine.   In the Business of Health segment, Barbara Lewis talks with Don about the gift and its focus on immunotherapy.

Immunotherapy is a new area of medical science. It’s the science of using the body’s own immune system to fight disease and it’s shown great promise in treating cancer.


Inside INdiana Business


Here are some of Don’s comments from the interview:

“We want to play our part in some of the exciting developments that are taking place in Immunotherapy.   It’s one of the hottest areas in all of science right now.  We’ve been struggling trying to find a cure for diseases like cancer for a long time, and we’re really seeing the promise of being able to turn our own immune systems toward that purpose.”

“I like to feel that I bring something in terms of knowledge of the software industry and cloud computing - those sorts of underlying technologies that are increasing important to all of medicine.”

“I’ve had a lot of fun studying cancer biology and immunology at Johns Hopkins and that more than anything convinced me that this was the right area to apply some resources and try to push it over the edge.”

When asked if he will focus on biotechnology and life sciences, Don said:

“Yes. To me life sciences are increasingly becoming an information science. It’s an area where I think I can contribute in some small way and where I intend to concentrate my efforts.”

“I’ve started up a new private company (LifeOmic) focusing on genomics and bioinformatics to leverage some of my software experience that hopefully can be helpful in other areas.”


IndyStar: $30M gift to IU Med could change how blood cancers are treated

If you've wondered what Don Brown, Founder and CEO of LifeOmic has been thinking regarding precision medicine these days, look no further than his recent $30 million donation to the Indiana University School of Medicine.

IndyStar reports, "Dr. Donald Brown, a 1985 IU med school graduate and founder of Interactive Intelligence, said he made the gift, the largest the medical school has received from an alumnus, to bolster the institution’s already strong research program in an area that has long interested him."

The LifeOmic Precision Medicine Portal takes a further step towards the promise of personalized medicine with a game-changing cloud-based healthcare solution that's built to store and manage complex biomedical information --  from whole genome sequences to large-scale data sets that include proteomics, metabolomics, transcriptomics, and others that have yet to be either discovered or effectively described and articulated.

We encourage you to read the level of commitment Don and LifeOmic are taking to the Precision Medicine Initiative...